Model for predicting anti-platelet curative effect of clopidogrel and application thereof

Abstract

The invention relates to a model for predicting an anti-platelet curative effect of clopidogrel and application thereof. The model comprises a data input unit, an assignment unit, a curative effect prediction unit and a report output unit, wherein the data input module is used for acquiring and inputting three independent risk factor data of CYP2C19 genotype, age and fibrinogen of a detected object and storing the data; the assignment module comprises a CYP2C19 genotype subunit, an age subunit and a fibrinogen subunit which are arranged in parallel, and the curative effect prediction unit receives assignment of the assignment module and performs clopidogrel anti-platelet curative effect prediction according to the total score of the assignment; and the report output unit outputs the prediction information of the curative effect prediction unit. Compared with the prior art, the model disclosed by the invention can be used for guiding accurate selection of a platelet P2Y12 receptor inhibitor, the predicted clopidogrel curative effect result is accurate and reliable, and balance can be achieved between antithrombotic benefit and bleeding risk.

Description

technical field [0001] The invention relates to the technical field of biological detection, in particular to a model for predicting the antiplatelet efficacy of clopidogrel and its application, which can be used to guide clinicians to accurately select platelet P2Y12 receptor inhibitors to evaluate the risk of ischemia and bleeding. Background technique [0002] In the occurrence and development of coronary heart disease, platelet activation is a key link, and it plays an important role in thrombotic events. Antiplatelet therapy is the cornerstone of coronary heart disease treatment. The number of patients with coronary heart disease in my country is increasing year by year, and nearly 1 million patients undergo percutaneous coronary intervention (PCI) each year, most of whom need to use platelet P2Y in combination with aspirin 12 receptor inhibitors, because dual antiplatelet therapy can effectively reduce the occurrence of acute ischemic events. Compared with ticagrelor,...

AI Technical Summary

Problems solved by technology

[0003] It is worth noting that there are obvious individual differences in the efficacy of clopidogrel, and the antiplatelet effect of the same dose of the drug on different patients is not the same

After more than 20% of patients take conventional doses of clopidogrel, their platelet aggregation ability has not been effectively inhibited, and the residual high platelet reactivity (high residual platelet reactivity, HRPR) makes these patients still suffer from stent thrombosis and myocardial infarction. at high risk

For patients with coronary heart disease in my country, if the treatment is only guided by the CYP2C19 genotype, it means that more than half of the patients need to replace clopidogrel, which is not only excessive but also inaccurate

The TAILOR-PCI study published at the 2020 ACC meeting also showed that relying solely on CYP2C19 genotype is not enough to guide individualized platelet therapy. This study is the largest so far to evaluate the use of CYP2C19 gene detection to guide the selection of antiplatelet strategies. The study population includes East Asian patients. Results did not meet the positive endpoint

However, the basic platelet activity index in this model needs to detect the thrombin-induced blood clot strength through thromboelastography, which will limit and affect its clinical application; because many hospitals do not have this instrument, and the instrument manufacturers do not will be different; for this reason, it is necessary to find a more general and unified index to reflect the patient's intrinsic thrombosis activity

Images